Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the risk of progression by 30% compared to Sanofi’s Aubagio.
The drug, a once-monthly injection that patients can administer themselves at home reduced relapse rates by 50.5% and 58.5% in trials compared with Sanofi’s, daily pill Aubagio.
The findings were announced at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
